Related Experiment Video
Updated: Aug 24, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Monoclonal antibody treatment of orbital lymphoma
Timothy J Sullivan1, David Grimes, Ian Bunce
1Department of Ophthalmology, University of Queensland, Royal Brisbane Hospital, Herston, Queensland, Australia. tjs@gil.com.au
Purpose:
To describe the use of an anti-CD20 monoclonal antibody, Rituximab, in the treatment of orbital lymphoma.
Methods:
Prospective, noncomparative, interventional case series of 8 patients treated with rituximab. Management, side effects, and outcome were recorded.
Results:
Five patients had initial complete response, 2 had partial response, and 1 had no response to this treatment. One patient had breathlessness, bronchospasm, and hypotension but was able to complete treatment. Mean follow-up was 16.5 months (range, 6 to 32 months).
Conclusions:
Rituximab is a safe and effective treatment in some cases of orbital lymphoma and may be used as an alternative to, or in conjunction with, other therapeutic modalities.
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
